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Aim: Various mutations have been identiﬁed in the Mediterranean fever (MEFV) gene which
is  reported to be responsible from Familial Mediterranean fever (FMF). In our study, we  aimed
to  determine the frequency of the MEFV mutations in our region and to investigate the
impact of G138G (rs224224, c.414A>G) and A165A (rs224223, c.495C>A) gene polymorphisms
on  the clinical ﬁndings of the disease.
Methods: One hundred and sixteen patients diagnosed with FMF and 95 control subjects
were included in this study. We  used the DNA sequence analysis method to identify the
most prevailing 10 mutations located in exon 2 and 10 of MEFV gene.
Results: As a result of the MEFV mutation analysis, the most common mutation was the
M694V mutation allele with a frequency rate of 41.8%. When the patients group and control
group were compared in terms of frequency of both polymorphic alleles (G polymorphic
allele, observed in G138G and the A polymorphic allele, observed in A165A), the variation
was observed to be statistically signiﬁcant (p < 0.001). It was found that the MEFV mutation
types have no relation with clinical ﬁndings and amyloidosis (p > 0.05).
Conclusions: To our knowledge, our study is the ﬁrst study in the Southern Marmara region
that  reports the frequency of MEFV mutations. Our ﬁndings imply that the polymorphisms
of  G138G and A165A may have an impact on progress of the disease. We think that more
studies, having higher number of cases and investigating the polymorphisms of MEFV gene,are  needed.
© 2016 Elsevier Editora Ltda. All rights reserved.Please cite this article in press as: Öksüz MF, et al. Investigation of MEFV gene polymorphisms (G138G and A165A) in adult patients with familial
Mediterranean fever. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.02.004
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Investigac¸ão de  polimorﬁsmos  no  gene  MEFV  (G138G  e  A165A)  em
pacientes  adultos  com  febre  mediterrânica  familiar
Palavras-chave:
Febre mediterrânica familiar
Gene MEFV
Polimorﬁsmo
r  e  s  u  m  o
Objetivo: Identiﬁcaram-se várias mutac¸ões no gene da febre mediterrânica (MEFV) que
relata-se que são responsáveis pela febre mediterrânica familiar (FMF). Este estudo teve
como objetivo determinar a frequência de mutac¸ões no MEFV na região sul do mar  de
Mármara e investigar o impacto dos polimorﬁsmos genéticos G138G (rs224224, c.414A>G) e
A165A (rs224223, c.495C>A) nos achados clínicos da doenc¸a.
Métodos: Foram incluídos neste estudo 116 pacientes com diagnóstico de FMF e 95 indivíduos
no  grupo controle. Utilizou-se o método de análise da sequência de DNA para identiﬁcar as
10  mutac¸ões mais prevalentes localizadas nos éxons 2 e 10 do gene MEFV.
Resultados: Como resultado da análise da mutac¸ão MEFV, a mutac¸ão mais comum foi
a  mutac¸ão alélica M694V, com uma taxa de frequência de 41,8%. Quando os grupos de
pacientes e controles foram comparados em termos de frequência de ambos os alelos
polimórﬁcos (alelo polimórﬁco G, observado no G138G e o alelo polimórﬁco A, observado
no  A165A), a variac¸ão observada foi estatisticamente signiﬁcativa (p < 0,001). Veriﬁcou-se
que  os tipos de mutac¸ão no MEFV não tinham relac¸ão com os achados clínicos nem com a
amiloidose (p > 0,05).
Conclusões: Que se tem conhecimento, este estudo é o primeiro realizado na região sul do
mar  de Mármara que relata a frequência de mutac¸ões no MEFV. Os achados indicam que os
polimorﬁsmos G138G e A165A podem ter um impacto sobre o progresso da doenc¸a. Acredita-
se  que são necessários mais estudos, abrangendo um maior número de casos e investigando
os  polimorﬁsmos do gene MEFV.
© 2016 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Familial Mediterranean fever (FMF) is an autosomal reces-
sively inherited inﬂammatory disease that affects people
from the Mediterranean region, including Turks, Armenians,
non-Ashkenazi Jews and Arabs. It is characterized by recur-
rent episodes of peritonitis, fever, rashes, arthritis and other
serosal inﬂammations.1–3 Although attacks are self-limited,
in some patients FMF  causes AA type amyloidosis that leads
to renal failure. Amyloidosis commonly causes other organ
damages besides renal failure. The prognosis is determined
by the complication of AA amyloidosis. The inﬂammatory
episodes and renal amyloidosis can be prevented by colchicine
therapy.2,4–6
FMF  is caused by mutations in MEFV gene. This gene
is located on the short arm of chromosome 16 and con-
sists of 10 exons. The protein, encoded by this gene and
termed pyrin/marenostrin, is present almost exclusively in
neutrophils and their precursors. This protein is involved
in regulation of inﬂammation, apoptosis and/or cytokine
secretion.4,7,8 The most common four mutations, M694V,
V726A, M680I, and M694I are found in the exon 10 of the
gene. Another mutation E148Q is found in the exon 2. These
ﬁve mutations are found in more  than two thirds of cases.2,9
A number of studies have shown that the M964V muta-
tion is associated with severe disease characterized with
early onset, high attack frequency, need for high doses ofPlease cite this article in press as: Öksüz MF, et al. Investigation of MEFV ge
Mediterranean fever. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.
colchicine, and high frequency of amyloidosis in untreated
patients. E148Q is found in populations in which FMF is
rare. E148Q mutation is also common but its role in thedisease is controversial. Most FMF experts refer to it as a
mutation causing mild disease.2,11–13 Many polymorphisms
like D102D (rs224225, c.306T>C), G138G (rs224224, c.414A>G),
A165A (rs224223, c.495C>A), R202Q (rs224222, c.605G>A) are
found within the exon 2 of MEFV gene. D102D, G138G and
A165A polymorphisms are synonymous variant. In a study,
Basarslan et al.14 reported that allele frequencies of G138G
and A165A polymorphisms were found to be higher in patients
with FMF.  In another study, Akar et al.15 claimed that 138Gly
allele carriers were more  prone to the development of amy-
loidosis and added that there was no statically signiﬁcant
difference in terms of G138G polymorphism between patients
and healthy subjects.14,15
In the present study, we  aimed to determine the frequency
of MEFV mutation in the Southern Marmara region and to
investigate the impact of G138G and A165A gene polymor-
phisms on the clinical ﬁndings of the disease.
Materials  and  methods
Study  subjects
We retrospectively reviewed the medical records of patients
with FMF followed in the department of Internal Medicine at
Uludag University Faculty of Medicine, Bursa, Turkey.
The patient group was created by selecting the adults in
whom MEFV gene mutation analysis was studied because ofne polymorphisms (G138G and A165A) in adult patients with familial
rbre.2016.02.004
presumptive diagnosis of FMF. The patient group consisted of
116 subjects in whom FMF diagnosis was veriﬁed clinically
(based on Tel-Hashomer criteria) and mutation was identiﬁed
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Table 1 – Clinical characteristics of the FMF  patient group
and control group.
FMF patient group
n = 116 (%)
Control group
n = 95(%)
p-Value
Gender (female/male) 61 (52.6)/55 (47.4) 51 (53.7)/44 (46.3) 0.9
Age (years)a 30 (18–79) 30 (18–71) 0.4
Abdominal pain 114 (98.3) – –
Fever 127 (74.1) – –
Arthritis/arthralgia 46 (33.6) – –
Erysipelas-like
erythema
14 (12.1) – –
Chest pain 14 (12.1) – –
Amyloidosis 7 (6) – –
a Median (minimum–maximum).
Table 2 – The allele frequencies of the most frequently
seen mutations.
Mutation Allele frequencya
M694V 41.8% (97/232)
M680I(G/C) 14.6% (34/232)
V726A 6% (14/232)
K695R 3.4% (8/232)
E148Q 2.1% (5/232)
In the present study, we evaluated the frequencies of the MEFV
gene mutations, the allele frequency of G138G and A165A
Table 3 – The distribution of MEFV mutations.
MEFV mutations Number of patients %
M694V/N 38 32.7
M694V/M694V 20 17.2
M680I(G/C)/N 11 9.4
M694V/M680I(G/C) 10 8.6
V726A/N 7 6
K695R/N 6 5.4
M680I(G/C)/M680I(G/C) 5 4.3
M694V/V726A 5 4.3
E148Q/N 4 3.4
M694V/M694I 2 1.7
M680I(G/C)/V726A 2 1.7
M694V/E148Q 1 0.9
M694V/R761M 1 0.9
M680I(G/C)/R761M 1 0.9
K695R/K695R 1 0.9
A744S/N 1 0.9r  e v b r a s r e u m a t o l
n MEFV gene. The control group consisted of 95 subjects
n whom the FMF  was excluded clinically and no mutation
as been identiﬁed in MEFV gene. Demographic data were
ecorded for both patients and control group. The study was
pproved by the Uludag University Ethics Committee.
NA  isolation  and  analysis  of  MEFV  gene
exons  2  and  10)
lood samples were obtained from patient and control groups
nd collected in EDTA tubes. Genomic DNA was extracted from
hole blood using different DNA isolation kit according to the
anufacturer’s instructions (Dr. Zeydanlı Life Sciences, Ltd.,
urkey; RTA Laboratuvarları Biyolojik Ürünler Ilac¸ ve Makine
an. Tic. A.S., Gebze, Kocaeli, Turkey).
The DNA fragments containing two exons of the MEFV gene
exons 2 and 10) were ampliﬁed by polymerase chain reaction
PCR) using the speciﬁc primers. PCR samples were analyzed
y direct sequencing of exons 2 and 10 of the MEFV gene in
n ABI-3130 DNA analyzer (Applied Bio systems, USA). After
equencing, the data were analyzed using DNA sequencing
nalysis v 5.2 software for most frequent mutations (E148Q,
694V, M680I, V726A, K695R, M694I, R761M, A744S) and poly-
orphisms of exon 2 (G138G and A165A).
tatistical  analysis
ges were represented as median (minimum–maximum)
alues and were compared between groups using the
ann–Whitney U test. In the comparison of categorical vari-
bles, Pearson’s chi-square, Yates chi-square test, and Fisher’s
xact test were used. All statistical analyses were performed
ith SPSS 13.0 (Chicago, IL). Statistical signiﬁcance was set at
 < 0.05.
esults
he study consisted of 116 adults with FMF  cases (61 female, 55
ale) and 95 control subjects (51 female, 44 male). There was
o signiﬁcant difference in gender or age between the groups
p = 0.9 and p = 0.4, respectively). The demographic and clinical
eatures of FMF  patients are shown in Table 1. In addition, 10
atients (8.6%) had chronic kidney disease and 15 (12.7%) had
roteinuria.
The frequency of the ﬁve the most common MEFV muta-
ions in this study are shown in Table 2.
The distribution of genotypes of MEFV gene (homozy-
ote, heterozygote, and compound heterozygote) is shown in
able 3. The distribution of genotypes (G138G and A165A) was
igniﬁcantly different between the groups of FMF  patients and
ontrols (p < 0.001, Table 4). For the G138G gene polymorphism,
he frequency of the G allele was 68% in FMF  patient group
nd 46% in control group (Fig. 1). For the A165A gene polymor-
hism, the frequency of the A allele was 67% in FMF  patient
roup and 45% in control group (Fig. 2). The allelic frequenciesPlease cite this article in press as: Öksüz MF, et al. Investigation of MEFV ge
Mediterranean fever. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.r
f both polymorphisms were statistically signiﬁcant different
etween the groups (p < 0.001).
There was no signiﬁcant relation between none of
he mutations nor the polymorphisms (G138G and A165A)a Total allele = 232.
and clinical ﬁndings like fever, abdominal pain, arthritis/
arthralgia, erysipelas-like erythema, chronic kidney disease,
proteinuria, or amyloidosis (p > 0.05 for all).
Discussionne polymorphisms (G138G and A165A) in adult patients with familial
bre.2016.02.004
R761M/N 1 0.9
Total 116 100
N, normal.
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Table 4 – MEFV genotype distribution among FMF  group
and control group.
FMF patient group
n = 116
Control group
n = 95
p-Value
G138G gene polymorphism (rs224224, c.414A>G)
<0.001
A/A genotype 12 (10.30) 30 (65.70)
A/G genotype 50 (43.10) 43 (31.30)
G/G genotype 54 (46.60) 22 (3)
A165A gene polymorphism (rs224223, c.495C>A)
<0.001
C/C genotype 12 (10.30) 30 (31.60)
C/A genotype 53 (45.70) 44 (46.30)
A/A genotype 51 (44) 21 (22.10)
100
90
80
70
60
50
40 32
68
A allele
frequency (%)
G allele
frequency (%)
30
20
10
0
Control
group
FMF
patient group
54
46
Fig. 1 – Distribution of the allele frequencies of MEFV gene
polymorphisms G138G gene polymorphism (rs224224,
c.414A>G) in the FMF  patient and control groups. The white
bars represent the frequency of the A allele, and the gray
bars represent the frequency of the G allele in both groups.
polymorphisms and clinical manifestations of the disease in
116 adult FMF  patients living in Bursa localized in the South-
ern Marmara region of Turkey. We  found signiﬁcantly higher
frequency of G allele of G138G and A allele of A165A polymor-
phisms. However, we  could not ﬁnd a signiﬁcant association
between these polymorphisms and clinical features in these
patients.
The estimated prevalence of the disease in Turkey is
0.1%. However, because many  patients are undiagnosed, it isPlease cite this article in press as: Öksüz MF, et al. Investigation of MEFV ge
Mediterranean fever. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.
thought that the prevalence may be higher. A disease-speciﬁc
laboratory test for the diagnosis of FMF  is not yet available.
Today, the diagnosis is provided on the basis of patient’s
100
90
80
70
60
50
40 33
67
30
20
10
0
Control
group
FMF
patient group
C allele
frequency (%)
A allele
frequency (%)
55
45
Fig. 2 – Distribution of the allele frequencies of MEFV gene
polymorphisms A138A gene polymorphism (rs224223,
c.495C>A) in the FMF  patient and control groups. The white
bars represent the frequency of the C allele, and the gray
bars represent the frequency of the A allele in both groups. 1 6;x  x x(x x):xxx–xxx
clinical features such as clinical ﬁndings, ethnicity, family his-
tory and colchicine response, etc.10,16
By Turkish FMF Study Group, clinical ﬁndings in patients
older than 18 years are listed as follows; abdominal pain
(93.7%), fever (92.5%), arthritis (27.1%) and erysipelas-like rash
(10.4%). In another study by Kasifoglu et al., clinical ﬁnd-
ings were listed as abdominal pain (94.6%), fever (91.9%),
arthritis (39.8%) and erysipelas-like rash (23.7%).17,18 Clinical
signs/symptoms other than fever are observed in similar rates
in the studies. Because of regular use of colchicine and tak-
ing nonsteroidal anti-inﬂammatory drug with the onset of
abdominal pain, frequency of fever may be determined rel-
atively lower.
Despite lack of information in terms of overall mutation
frequency in studies conducted in our country, the muta-
tion frequencies of different regions were reported in studies
from those regions. Turkish FMF  Study Group assessed many
patients and healthy people in 2005. According to this report,
genetic analysis was performed in 1090 patients and most
common mutations were detected in to the following rates,
M694V 51.4%, M680I 14.4% and V726A 8.6%.17 Based on the
study conducted by Turkish FMF Study Group, it is considered
that the genetic diagnosis of FMF  can be made by determina-
tion of these three mutations in the majority of patients (about
74%).
In studies conducted in various regions of Turkey, similar
results to the rates speciﬁed by Turkish FMF  Study Group have
been reported. Gunesacar et al.19 reported that the most com-
mon  mutations in 90 patients around C¸ ukurova region were
M694V (51.66%), M680I (17.22%), V726A (10.55%), and M694I
(1.66%). In a study made by Akar et al.20 in Central Ana-
tolia Region, mutation frequencies of M694V, M680I, V726A,
and M694I were determined as 43.5%, 12%, 11.1% and 2.8%,
respectively. In another study from Erzurum, Ertekin et al.21
determined M694V (51.3%) as the most common type of muta-
tion. It was followed by M680 (7.3%), V726A (4.9%), E148Q (4.9%)
and R761H (2.4%), respectively. According to a study made by
Yilmaz et al.22 around Ankara, the frequencies of mutations
in patients were found as follows; 51.55% M694V, 9.22% M680I,
8.8% V726A, 3.55% E148Q, and 0.44% M694I. In recent studies,
the mutation frequencies of M694V, M680I, V726A were deter-
mined as 33.7%, 15.5%, 5%, respectively by Yigit et al.23 in Black
Sea region; the mutation frequencies of M694V, E148Q, V726A,
and M680I were determined as 47.6%, 16.75%, 12.95%, 11.94%,
respectively by Akin et al.2 in the Aegean region. In another
recent study from Ankara, Dog˘an et al.3 reported the muta-
tion frequencies as follows: 42.05% M694V, 19.27% E148Q, and
16.27% M680I. In our study, mutation frequencies are similar
to the results of Turkish FMF Study Group.
FMF is a clinical diagnosis, which can be supported but
not excluded by genetic testing. The authors recommended
the use of genetic testing only in atypical cases when there
are doubts about the clinical diagnosis.24 Type of mutation
is thought to be useful to know for conﬁrmation of diagno-
sis and determining the management of complications that
may occur based on the types of mutation. FMF  patientsne polymorphisms (G138G and A165A) in adult patients with familial
rbre.2016.02.004
carrying two of the common mutated alleles (homozygotes
or compound heterozygotes), especially for M694V mutation
or mutations at position 680–694 on exon 10, must be con-
sidered at risk of having a more  severe disease.24 Patients
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omozygous for M694V mutation are at risk of early onset
isease and developing complication of amyloidosis.18 It is
lso well known that amyloidosis is a risk for renal failure.
t is reported that the initiation of colchicine signiﬁcantly
educed complications in patients clinically diagnosed at an
arly stage.25,26
In a report of Turkish FMF  Study group, joint com-
laints were signiﬁcantly more  frequent in M694V/M694V
omozygous patients while there was no statically signiﬁcant
ifference in correlation analysis between mutations and clin-
cal ﬁndings such as fever, abdominal pain, and amyloidosis.17
In our study, it is was observed that there was no statically
igniﬁcant relation between mutation types and frequen-
ies of chronic kidney disease, amyloidosis, proteinuria, and
ymptoms like fever, abdominal pain, arthritis, arthralgia,
rysipelas-like erythema. To our knowledge, our study is
mportant because of being ﬁrst study to report the frequency
f MEFV mutations in the Southern Marmara region.
Failure to set out exactly the genotype–phenotype rela-
ionship with the known classical mutations, has attracted
ttention to the polymorphisms of which clinical signiﬁcance
s not well-known. In literature, the relationship between
olymorphisms of G138G (rs224224), A165A (rs224223), R202Q
rs224222) in exon 2 of MEFV gene and disease and its compli-
ations is reported in a small number of publications.14,15,27
In a study from our country, Öztürk et al. reported that car-
iage of R202Q polymorphism did not have any effects in terms
f FMF  disease, but also it was stated that the mutations in
xon 10 of this gene affected the symptoms of the disease.27
In a study by Akar et al.,15 124 patients with FMF and
1 healthy controls were included and Ala138Gly polymor-
hism was investigated. Between patient and control groups,
here was no statically signiﬁcant difference in terms of and
la138Gly polymorphism. However, when 47 patients with
myloidosis were compared with other patients in whom
myloidosis was not detected, signiﬁcant difference was
bserved in terms of Ala138Gly polymorphism and polymor-
hic allele of 138Gly in patients with FMF  was reported to be
ssociated with amyloidosis. In the study by Basarslan et al.,14
he frequencies of polymorphic alleles of G138G (rs224224)
nd A165A (rs224223) in patients were higher than the control
roup.
In our study, signiﬁcant difference was detected in terms
f G138G and A165A polymorphisms in comparison of the
atients and healthy subjects. In addition, in our study, unlike
he other studies, relationship between G138G and A165A
olymorphisms and clinical features such as fever, abdominal
ain, arthritis/arthralgia, erysipelas-like erythema, chronic
enal disease, proteinuria, and amyloidosis was investigated.
owever, there was no statically signiﬁcant association. Small
umber of patients and patients’ ages (all of them were over
8) in our group may have affected our results.
In this study there was signiﬁcant differences between the
atient and control groups in terms of G138G and A165A poly-
orphisms. These ﬁndings need to be evaluated in further
tudies with larger number of cases and follow-up data toPlease cite this article in press as: Öksüz MF, et al. Investigation of MEFV ge
Mediterranean fever. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.r
etermine the relationship between phenotype and the impli-
ations for the development of disease complications clearly.
Among the limitations of our study are the cross sectional
esign, the relatively small sample size, and small number
1 6;x  x x(x x):xxx–xxx 5
of patients with amyloidosis (7 patients), and exclusion of
patients under 18 years old. We  believe that further studies
with larger sample sizes and longitudinal design are needed
to elucidate the exact role of mutations and polymorphisms
in the clinical context and the prognosis of FMF patients.
In conclusion, to our knowledge, our study is the ﬁrst
report of the South Marmara region determining frequencies
of MEFV mutations, and the frequencies of MEFV mutations
in our region were observed at similar rates as in the litera-
ture. Besides, polymorphic alleles of G138G and A165A were
observed in a higher frequency in FMF  patients compared
with controls. However, we did not observe any association
between these mutations or polymorphisms in these patients.
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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